MEIP Is A Small-Cap With Big Potential Into December!

Sign Up For Our FREE E-mail Newsletter-> HERE <-To Receive Our Penny Stock Expert Picks Now!

Visit our Twitter page for real-time updates, click here: Penny Stock Experts

Hi Everyone & Welcome New Subscribers,

Our week with TPIV (TapImmune, Inc.) started where we left off, closing even on the day at .61 with over 250K shares traded, continuing to churn in this range until deciding what it really wants to do (which we believe is to go up in a big way, again).

While TPIV continues to warm up, we have our eyes on other prospects operating in a similar space, more specifically MEIP (MEI Pharma, Inc.) which trades on the NASDAQ and could have a very exciting end to 2015.

MEIP (MEI Pharma, Inc.) plans to unveil Phase II clinical results for their drug, Pracinostat, which is being developed for advanced hematologic diseases such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), at the 2015 American Society of Hematology (ASH) Program Committee on December 7th. 

It should be noted that last year at this time MEIP traded up near $8 a share, but after bad news in March of this year that a different Phase II trial failed to reach it’s primary end point, the share price dropped from $6 to less than $2 overnight.

Following today’s price action, we are going to be looking to establish a position near the $1.65 range, maybe higher or lower depending on how the price sustains itself over the next few sessions.

Keep MEIP on top of your radar into December, as we believe results could be much better this time around!

Happy Trading!

Sign up-> NOW <-To Join Our E-mail List!

Happy Trading!


The Penny Stock Experts Team At

Please read our legal Disclaimer below:

We have no communication with any of the company’s mentioned nor any affiliates. We hold no position in MEIP or TPIV at the current time, but plan to trade and/or establish a position in both stocks over the short term and will update our blog accordingly.

This disclaimer is to be read in its entirety, and fully understood before using or joining the email list. reserves the right to revise, amend, or modify our Privacy Policy, our Disclaimer, and our other policies and agreements at any time and in any manner by updating their postings. You are responsible for regularly reviewing these terms, conditions, and notices, and any additional terms posted on Your continued use of the website and/or email newsletter after the effective date of such changes constitutes your acceptance of and agreement to such changes. If we should update this disclaimer, we will post the updates to this page on DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS.

Neither nor any of its employees, affiliates, subsidiaries, or family members are registered investment advisers or registered st ock brokers either within the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority and shall not be liable for any direct, indirect, incidental, special or consequential damages arising out of, or resulting from the use or inability to use this site, including but not limited to damages for the loss of capital, funds, profits, use, data, or any and all other possible damages, even if such party has been advised of the possibility of such damages resulting from the use of this site and all information contained on this site.

We are neither licensed nor qualified to provide investment advice. The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the company’s profiled based solely on information contained in our newsletter or website.

Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research. may buy or sell shares on the open market that may positively or negatively affect the stock price before or after this mailing and subscribers are to be fully aware that and it’s affiliates can buy or sell more shares at any time. We can add or decrease this position at anytime following this e-mail or post. and/or it’s affiliates may receive compensation for e-mail alerts.

To view our full compensation disclosure please visit does not accept free-trading shares as a form of payment.